<DOC>
	<DOCNO>NCT01480245</DOCNO>
	<brief_summary>The purpose study explore long-term safety , tolerability efficacy GSK2402968 DMD subject previously participate either DMD114117 DMD114044 .</brief_summary>
	<brief_title>Open Label Study GSK2402968 Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Previous participation either DMD114117 DMD114044 Continued use glucocorticoid Willing able comply protocol requirement Able give inform consent French subject : Eligible inclusion either affiliate beneficiary social security category . Subject experience serious adverse event meet safety stop criterion remain unresolved DMD114117 DMD114044 , opinion investigator could attributable study medication ongoing , Use anticoagulant , antithrombotics antiplatelet agent , previous treatment investigational drug , except GSK2402968 , within 1 month first administration study medication , Current anticipate participation investigational clinical study , History significant medical disorder may confound interpretation either efficacy safety data e.g . current history renal liver disease/impairment , history inflammatory disease .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>968</keyword>
	<keyword>Duchenne</keyword>
	<keyword>DMD</keyword>
	<keyword>drisapersen</keyword>
</DOC>